Clinical trial of camrelizumab combined with chemotherapy in the treatment of patients with advanced esophageal squamous cell carcinoma
10.13699/j.cnki.1001-6821.2024.16.003
- VernacularTitle:卡瑞利珠单抗联合化疗治疗晚期食管癌患者的临床研究
- Author:
Han XUAN
1
;
Hao-Wu LI
;
Guo-He LIN
;
Geng SONG
Author Information
1. 安徽医科大学第二附属医院肿瘤科,安徽合肥 230062
- Keywords:
camrelizumab;
esophageal squamous cell carcinoma;
chemotherapy;
immune function;
clinical curative effect;
survival benefit
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(16):2316-2319
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect and survival benefits of camrelizumab combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma(ESCC).Methods Patients with advanced ESCC were divided into control group and treatment group.The control group was given albumin-paclitaxel(260 mg·m-2,qd,intravenous drip on the 1st day)and cisplatin(20 mg·m-2,once a day,intravenous drip on the 1 st-5 th day),while treatment group was given camrelizumab(200 mg,qd,intravenous drip on the 1st day)on basis of control group.All patients were treated for 4 cycles(21 d/cycle).The curative effect(disease control rate,objective response rate),immune function(CD4+,CD8+,CD4+/CD8+),tumor markers(carbohydrate antigen 199,carcinoembryonic antigen,carbohydrate antigen 125),safety and survival benefits in the two groups were compared after treatment.Results There were 48 cases in treatment group and 42 cases in control group.After treatment,disease control rates in treatment group and control group were 79.17％(38 cases/48 cases)and 57.14％(24 cases/42 cases),objective response rates were 62.50％(30 cases/48 cases)and 40.48％(17 cases/42 cases),the differences were statistically significant(all P＜0.05).After treatment,levels of peripheral blood CD4+/CD8+levels were 1.11±0.29 and 1.87±0.38;levels of levels of serum carbohydrate antigen 199 were(50.03±6.21)and(36.41±4.87)ng·mL-1;levels of serum carcinoembryonic antigen were(21.25±3.39)and(14.97±2.85)ng·mL-1;levels of serum carbohydrate antigen 125 were(29.82±4.16)and(20.63±3.34)ng·mL-1,the differences were statistically significant(all P＜0.05).The differences in 6-month survival rate between treatment group and control group were statistically significant[95.83％(46 cases/48 cases)vs 80.95％(34 cases/42 cases),P＜0.05].The adverse drug reactions of the two groups were mainly proteinuria,abnormal liver function,bone marrow suppression,abnormal thyroid function and gastrointestinal reaction,and there was no significant difference in the incidence of adverse drug reactions between the two groups(P＞0.05).Conclusion Camrelizumab combined with chemotherapy can enhance immune function in patients with advanced ESCC,inhibit the expressions of tumor markers and increase survival rate.
